Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans

Journal of Psychopharmacology

Volumn 25, Issue 11, 2011, Pages 1469-1479

  Lile, Joshua A ^a   Stoops, William W ^a,b   Glaser, Paul Ea ^a   Hays, Lon R ^a   Rush, Craig R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Aripiprazole; cocaine; drug discrimination; partial agonist; psychomotor performance; subjective effects

Indexed keywords

ARIPIPRAZOLE; COCAINE;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; DRUG MECHANISM; FEMALE; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SELF REPORT; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; BEHAVIOR; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; DEXTROAMPHETAMINE; DISCRIMINATION LEARNING; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUESTIONNAIRES; QUINOLONES; SUBSTANCE-RELATED DISORDERS;

EID: 83455231389     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110385597     Document Type: Article

References (67)

1. Angrist B, Corwin J, Bartlik B, Cooper T. Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry. 1987 ; 22: 1357-1368 (Pubitemid 18046652)
2. Barrett RL, Appel JB. Effects of stimulation and blockade of dopamine receptor subtypes on the discriminative stimulus properties of cocaine. Psychopharmacology. 1989 ; 99: 13-16 (Pubitemid 19201707)
3. Bergman J. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify). Exp Clin Psychopharmacol. 2008 ; 16: 475-483
4. Boulton DW, Kollia G, Mallikaarjun S, Komoroski B, Sharma A, Kovalick LJ, et al. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet. 2008 ; 47: 475-485 (Pubitemid 351861959)
5. Caine SB, Negus SS, Mello NK, Bergman J. Effects of dopamine D1-like and D2-like agonists in rats trained to discriminate cocaine from saline: Influence of experimental history. Exp Clin Psychopharmacol. 2000 ; 8: 404-414
6. Callahan PM, Cunningham KA. Discriminative stimulus properties of cocaine in relation to dopamine D2 receptor function in rats. J Pharmacol Exp Ther. 1993 ; 266: 585-592 (Pubitemid 23318665)
7. Callahan PM, Cunningham KA. Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists. Neuropharmacology. 1997 ; 36: 373-381 (Pubitemid 27198698)
8. Callahan PM, Appel JB, Cunningham KA. Dopamine D1 and D2 mediation of the discriminative stimulus properties of d-amphetamine and cocaine. Psychopharmacology. 1991 ; 103: 50-55
9. Chait LD, Uhlenhuth EH, Johanson CE. The discriminative stimulus and subjective effects of d-amphetamine in humans. Psychopharmacology. 1985 ; 86: 307-312 (Pubitemid 15064956)
10. Childress AR, O'Brien CP. Dopamine receptor partial agonists could address the duality of cocaine craving. Trend Pharmacol Sci. 2000 ; 21: 6-9 (Pubitemid 30102182)
11. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005 ; 45: 89-93
12. Di Marino ME, Haberny KA, Felch LJ, Walsh SL, Preston KL and Bigelow GE (1998) Development of a subjective rating scale sensitive to acute cocaine administration. National Institute on Drug Abuse Research Monograph Series, Problems of Drug Dependence, 1997: Proceedings of the 59th Annual Scientific Meeting 178: 139.
13. Feltenstein MW, Altar CA, See RE. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry. 2007 ; 61: 582-590 (Pubitemid 46328850)
14. Filip M, Przegaliński E. The role of dopamine receptor subtypes in the discriminative stimulus effects of amphetamine and cocaine in rats. Pol J Pharmacol. 1997 ; 49: 21-30 (Pubitemid 27234319)
15. Garner KJ, Baker LE. Analysis of D2 and D3 receptor-selective ligands in rats trained to discriminate cocaine from saline. Pharmacol Biochem Behav. 1999 ; 64: 373-378 (Pubitemid 29438625)
16. Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B, et al. Low-dose caffeine discrimination in humans. J Pharmacol Exp Ther. 1990 ; 252: 970-978 (Pubitemid 20127398)
17. Haney M, Spealman R. Controversies in translational research: drug self-administration. Psychopharmacology. 2008 ; 199: 403-419
18. Heishman SJ, Henningfield JE. Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans. Psychopharmacology. 1991 ; 103: 436-442
19. Hughes AM, Lynch P, Rhodes J, Ervine CM, Yates RA. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. Br J Clin Pharmacol. 1999 ; 48: 323-330 (Pubitemid 29417714)
20. Inaba T. Cocaine: pharmacokinetics and biotransformation in man. Can J Physiol Pharmacol. 1989 ; 67: 1154-1157 (Pubitemid 20002378)
21. Jasinski D Drug Addiction I. Morton WR, ed. New York: Springer-Verlag ; 1977 :
22. Jiménez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. Drugs. 2009 ; 69: 1319-1338
23. Kantak KM, Edwards MA, Spealman RD. Effects of N-methyl-D-aspartate antagonists in rats discriminating different doses of cocaine: comparison with direct and indirect dopamine agonists. J Pharmacol Exp Ther. 1995 ; 274: 657-665
24. Kosten TA, DeCaprio JL, Nestler EJ. Long-term haloperidol administration enhances and short-term administration attenuates the behavioral effects of cocaine in a place conditioning procedure. Psychopharmacology. 1996 ; 128: 304-312 (Pubitemid 26403126)
25. LeDuc PA, Mittleman G. Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. Psychopharmacology. 1993 ; 110: 427-436 (Pubitemid 23074566)
26. Lile JA, Stoops WW, Hays LR, Rush CR. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period. Am J Drug Alcohol Abuse. 2008 ; 34: 721-729
27. Lile JA, Stoops WW, Vansickel AR, Glaser PE, Hays LR, Rush CR. Aripiprazole attenuates the discriminative-stimulus effects of d-amphetamine in humans. Neuropsychopharmacology. 2005 ; 30: 2103-2114 (Pubitemid 43093509)
28. Liu Y, Sun HQ, Bao YP, Li SX, Beveridge TJ, Di XL, et al. Subjective, cognitive/psychomotor and physiological effects of aripiprazole in Chinese light and heavy smokers. Drug Alcohol Depend. 2009 ; 101: 42-52
29. McLeod DR, Griffiths RR, Bigelow GE, Yingling JE. An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instr. 1982 ; 14: 463-466
30. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004 ; 44: 179-187 (Pubitemid 38114317)
31. Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet. 2008 ; 47: 533-542 (Pubitemid 351969827)
32. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971 ; 12: 245-258
33. Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry. 2004 ; 28: 1213-1219 (Pubitemid 39592919)
34. Newton TF, Reid MS, De La Garza R, Mahoney JJ, Abad A, Condos R, et al. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2008 ; 11: 1037-1045
35. Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW. Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther. 1992 ; 261: 885-894
36. Oliveto AH, Rosen MI, Woods SW, Kosten TR. Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans. J Pharmacol Exp Ther. 1995 ; 272: 231-241
37. Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009 ; 69: 577-607
38. Peltier RL, Emmett-Oglesby MW, Thomas WH, Schenk S. Failure of ritanserin to block the discriminative or reinforcing stimulus effects of cocaine. Pharmacol Biochem Behav. 1994 ; 48: 473-478 (Pubitemid 24197368)
39. Przegaliñski E, Filip M. Stimulation of serotonin (5-HT)1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats. Behav Pharmacol. 1997 ; 8: 699-706 (Pubitemid 28040001)
40. Pulvirenti L, Koob GF. Being partial to psychostimulant addiction therapy. Trends Pharmacol Sci. 2002 ; 23: 151-153 (Pubitemid 34270586)
41. Rush CR, Baker RW. Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp Clin Psychopharmacol. 2001 ; 9: 59-73 (Pubitemid 32852215)
42. Rush CR, Baker RW, Wright K. Acute physiological and behavioral effects of oral cocaine in humans: a dose-response analysis. Drug Alcohol Depend. 1999 ; 55: 1-12 (Pubitemid 29221998)
43. Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol. 1998 ; 6: 32-44 (Pubitemid 28102884)
44. Rush CR, Stoops WW, Hays LR, Glaser PEA, Hays LS. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther. 2003 ; 306: 195-204 (Pubitemid 36734373)
45. Schama KF, Howell LL, Byrd LD. Serotonergic modulation of the discriminative-stimulus effects of cocaine in squirrel monkeys. Psychopharmacology. 1997 ; 132: 27-34 (Pubitemid 27303736)
46. Selzer ML. The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am J Psychiatry. 1971 ; 127: 1653-1658
47. Sevak RJ, Stoops WW, Hays LR, Rush CR. Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther. 2009 ; 328: 1007-1018
48. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003 ; 28: 1400-1411 (Pubitemid 41070874)
49. Sinnott RS, Mach RH, Nader MA. Dopamine D2/D3 receptors modulate cocaine's reinforcing and discriminative stimulus effects in rhesus monkeys. Drug Alcohol Depend. 1999 ; 54: 97-110 (Pubitemid 29114988)
50. Skinner HA. The Drug Abuse Screening Test. Addict Behav. 1982 ; 7: 636-671
51. Smith BJ, Jones HE, Griffiths RR. Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. Psychopharmacology. 2001 ; 156: 435-444 (Pubitemid 32695853)
52. Song M, Xu X, Hang T, Wen A, Yang L. Development of an LC-MS/MS method for the simultaneous quantification of aripiprazole and dehydroaripiprazole in human plasma. Anal Biochem. 2009 ; 385: 270-277
53. Sørensen G, Sager TN, Petersen JH, Brennum LT, Thøgersen P, Hee Bengtsen C, et al. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Psychopharmacology. 2008 ; 199: 37-46
54. Soto PL, Katz JL. Fluoxetine does not alter the ability of dopamine D(1)- and D(2)-like agonists to substitute for cocaine in squirrel monkeys. Pharmacol Biochem Behav. 2009 ; 92: 219-223
55. Spealman RD. Discriminative stimulus effects of cocaine in squirrel monkeys: lack of antagonism by the dopamine D2 partial agonists terguride, SDZ 208-911, and SDZ 208-912. Pharmacol Biochem Behav. 1995 ; 51: 661-665
56. Spealman RD, Bergman J, Madras BK, Melia KF. Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. J Pharmacol Exp Ther. 1991 ; 258: 945-953
57. Stoops WW, Lile JA, Glaser PE, Rush CR. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend. 2006 ; 84: 206-209 (Pubitemid 44119096)
58. Stoops WW, Lile JA, Lofwall MR, Rush CR. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. Am J Drug Alcohol Abuse. 2007 ; 33: 769-776 (Pubitemid 350125771)
59. Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies ; 2009 :
60. Thomsen M, Fink-Jensen A, Woldbye DP, Wörtwein G, Sager TN, Holm R, et al. Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats. Psychopharmacology. 2008 ; 201: 43-53
61. Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry. 2007 ; 164: 160-162 (Pubitemid 46154797)
62. Van Dyke C, Jatlow P, Ungerer J, Barash PG, Byck R. Oral cocaine: plasma concentrations and central effects. Science. 1978 ; 200: 211-213 (Pubitemid 8310535)
63. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C, et al. Reinforcing effects of stimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. J Pharmacol Exp Ther. 1999 ; 291: 409-415 (Pubitemid 29451617)
64. Voronin K, Randall P, Myrick H, Anton R. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm-possible influence of self-control. Alcohol Clin Exp Res. 2008 ; 32: 1954-1961
65. Wee S, Wang Z, Woolverton Z, Pulvirenti L, Koob GF. Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology. 2007 ; 32: 2238-2247 (Pubitemid 47417701)
66. Wilkinson P, Van Dyke C, Jatlow P, Barash P, Byck R. Intranasal and oral cocaine kinetics. Clin Pharmacol Ther. 1980 ; 27: 386-394 (Pubitemid 10099126)
67. Witkin JM, Nichols DE, Terry P, Katz JL. Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J Pharmacol Exp Ther. 1991 ; 257: 706-713